WHY IT MATTERS: If you are a parent, caregiver, or young adult patient, this research reinforces that cannabis therapies should be reserved for adults with clinical oversight, and that adolescent use without medical necessity carries real psychiatric risk. CLINICAL OVERVIEW: Large-scale research continues to reinforce what clinicians have observed for years: adolescent cannabis use is associated with increased risk of psychotic disorders, depression, and anxiety later in life. The developing brain, particularly before age 25, is uniquely vulnerable to the effects of THC on endocannabinoid system signaling, and early exposure may alter neurodevelopmental trajectories in ways that increase psychiatric risk.